Hirschsprung's disease. Management
Alimentary Pharmacology & Therapeutics · 2024-07 · 60 (S1)
DOI: 10.1111/apt.18068 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 25.06.2024. Verfasst von Claudio Morera und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Motility and Functional Gastrointestinal Disorders, Children's Hospital Boston, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Hirschsprung Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 97 Literaturangaben.
Abstract (Originalsprache)
Background
Hirschsprung's disease (HD) is a rare congenital disease that is characterised by the absence of ganglion cells in the myenteric plexus starting in the distal bowel. This results in distal functional obstruction and may lead to complications like enterocolitis. The treatment is surgical and requires the resection of the aganglionic segment, and the pull‐through of normal intestine into the anal opening. However, even after successful surgery, patients may continue to have symptoms.
Aim
Discuss current surgical techniques and management strategies for patients with postoperative symptoms after surgical correction of Hirschsprung's disease.
Methods
A review of the literature was done through PubMed, with a focus on clinical management and approach.
Results
We describe the clinical problems that can occur after surgical correction. These include obstructive symptoms, enterocolitis, or faecal incontinence. A systematic approach for the evaluation of these patients includes the exclusion of anatomic, inflammatory, behavioural or motility related factors. Depending on the severity of the symptoms, the evaluation includes examination under anaesthesia, the performance of contrast studies, endoscopic studies, measurement of anal sphincter function and colonic motility studies. The treatment is focused towards addressing the different pathophysiological mechanisms, and may include medical management, botulinum toxin to the anal sphincter or rarely redo‐operation.
Conclusions
Patients with Hirschsprung's disease need to have surgical correction, and their postoperative long‐term management is complex given a variety of associated problems that can occur after surgery. A systematic evaluation is necessary to provide appropriate therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for Motility and Functional Gastrointestinal Disorders, Children's Hospital Boston, Boston, Massachusetts, USA.
ORCID-Profile: Samuel Nurko
Zitieren
APA
Morera, C., & Nurko, S. (2024). Hirschsprung's disease. Management. Alimentary Pharmacology & Therapeutics, 60(S1). https://doi.org/10.1111/apt.18068
Vancouver
Morera C, Nurko S. Hirschsprung's disease. Management. Alimentary Pharmacology & Therapeutics. 2024;60(S1). doi:10.1111/apt.18068
BibTeX
@article{Morera2024,
author = {Morera, Claudio and Nurko, Samuel},
title = {Hirschsprung's disease. Management},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {S1},
doi = {10.1111/apt.18068}
}
EUVIMED